Identification

Name
Didanosine
Accession Number
DB00900  (APRD00240, DB02392)
Type
Small Molecule
Groups
Approved
Description

A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite. [PubChem]

Structure
Thumb
Synonyms
  • 2,3-Dideoxyinosine
  • 9-((2R,5S)-5-(Hydroxymethyl)-tetrahydrofuran-2-yl)-1H-purin-6(9H)-one
  • 9-((2R,5S)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-1,9-dihydro-purin-6-one
  • 9-((2S,5R)-5-Hydroxymethyl-tetrahydro-furan-2-yl)-9H-purin-6-ol
  • 9-[(2R,5S)-5-(Hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one
  • DDI
  • DdIno
  • Didanosina
  • Didanosine
  • Didanosinum
  • Dideoxyinosine
External IDs
BMY-40900 / DDI
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VidexPowder, for solution10 mg/1mLOralBristol Myers Squibb1991-10-09Not applicableUs
VidexPowder, for solution10 mg/1mLOralBristol Myers Squibb1991-10-09Not applicableUs
Videx Chewable Dispersible Tab 100mgTablet100 mgOralBristol Myers Squibb1991-12-312008-03-27Canada
Videx Chewable Dispersible Tab 150mgTablet150 mgOralBristol Myers Squibb1991-12-312007-05-01Canada
Videx Chewable Dispersible Tab 25mgTablet25 mgOralBristol Myers Squibb1991-12-312007-01-02Canada
Videx Chewable Dispersible Tab 50mgTablet50 mgOralBristol Myers Squibb1991-12-312005-08-01Canada
Videx ECCapsule, delayed release400 mgOralBristol Myers Squibb2002-01-02Not applicableCanada
Videx ECCapsule, delayed release400 mg/1OralBristol Myers Squibb2000-10-31Not applicableUs
Videx ECCapsule, delayed release125 mgOralBristol Myers Squibb2002-01-02Not applicableCanada
Videx ECCapsule, delayed release125 mg/1OralBristol Myers Squibb2000-10-31Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DidanosineCapsule, delayed release125 mg/1OralAurobindo Pharma2008-09-24Not applicableUs
DidanosinePowder, for solution10 mg/1mLOralAurobindo Pharma2007-03-082014-08-18Us
DidanosineCapsule, delayed release200 mg/1OralMylan Pharmaceuticals2010-06-282016-06-30Us
DidanosineCapsule, delayed release pellets250 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs53808 023620180907 15195 ohv6wg
DidanosineCapsule, delayed release400 mg/1OralAmerincan Health Packaging2009-12-082011-01-31Us
DidanosineCapsule, delayed release pellets250 mg/1OralTeva Pharmaceuticals USA, Inc.2004-12-152019-03-31Us0555 058920180913 8702 3apqol
DidanosineCapsule, delayed release250 mg/1OralAmerincan Health Packaging2009-12-082012-01-31Us00555 0589 01 nlmimage10 172f8b9c
DidanosineCapsule, delayed release250 mg/1OralAurobindo Pharma2008-09-24Not applicableUs
DidanosineTablet, for suspension100 mg/1OralAurobindo Pharma2012-01-232012-09-30Us65862 09220180907 15195 1enkd6h
DidanosineCapsule, delayed release400 mg/1OralMylan Pharmaceuticals2010-06-282016-06-30Us
Categories
UNII
K3GDH6OH08
CAS number
69655-05-6
Weight
Average: 236.2273
Monoisotopic: 236.09094027
Chemical Formula
C10H12N4O3
InChI Key
BXZVVICBKDXVGW-NKWVEPMBSA-N
InChI
InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
IUPAC Name
9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one
SMILES
OC[C@@H]1CC[C@@H](O1)N1C=NC2=C1NC=NC2=O

Pharmacology

Indication

For use, in combination with other antiretroviral agents, in the treatment of HIV-1 infection in adults.

Associated Conditions
Pharmacodynamics

Didanosine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Didanosine differs from other nucleoside analogues, as it does not have any of the regular bases, instead it has hypoxanthine attached to the sugar ring. Didanosine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. Didanosine is effective against HIV, and usually used in combination with other antiviral therapy. Switching from long term AZT treatment to didanosine has been shown to be beneficial. Didanosine has weak acid stability and therefore, it is often combined with an antacid.

Mechanism of action

Didanosine (ddI) is metabolized intracellularly by a series of cellular enzymes to its active moiety, dideoxyadenosine triphosphate (ddATP), which inhibits the HIV reverse transcriptase enzyme competitively by competing with natural dATP. It also acts as a chain terminator by its incorporation into viral DNA as the lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.

TargetActionsOrganism
AReverse transcriptase/RNaseH
inhibitor
Human immunodeficiency virus 1
UPurine nucleoside phosphorylaseNot AvailableHuman
Absorption

Rapidly absorbed (bioavailability 30-40%) with peak plasma concentrations appearing within 0.5 and 1.5 hrs.

Volume of distribution
Not Available
Protein binding

Low (<5%)

Metabolism

Rapidly metabolized intracellularly to its active moiety, 2,3-dideoxyadenosine-5-triphosphate (ddA-TP). It is then further metabolized hepatically to yield hypoxanthine, xanthine, and uric acid.

Route of elimination

Based on data from in vitro and animal studies, it is presumed that the metabolism of didanosine in man occurs by the same pathways responsible for the elimination of endogenous purines. Purines are eliminated by the kidneys.

Half life

30 minutes in plasma and more than 12 hours in intracellular environment.

Clearance
Not Available
Toxicity

Side effects include pancreatitis, peripheral neuropathy, diarrhea, hyperuricemia and hepatic dysfunction

Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategory
Didanosine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbacavirDidanosine may decrease the excretion rate of Abacavir which could result in a higher serum level.
AbafunginDidanosine can cause a decrease in the absorption of Abafungin resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcarboseAcarbose may decrease the excretion rate of Didanosine which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Didanosine which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Didanosine which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Didanosine which could result in a higher serum level.
AcetazolamideThe excretion of Didanosine can be decreased when combined with Acetazolamide.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Didanosine which could result in a higher serum level.
AclidiniumDidanosine may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineDidanosine may decrease the excretion rate of Acrivastine which could result in a higher serum level.
Food Interactions
  • Avoid alcohol.
  • Take on empty stomach: 1 hour before or 2 hours after meals.

References

Synthesis Reference

Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy, Kesireddy Subash Chander Reddy, "Novel Process for the Preparation of Didanosine Using Novel Intermediates." U.S. Patent US20080293938, issued November 27, 2008.

US20080293938
General References
Not Available
External Links
Human Metabolome Database
HMDB0015037
KEGG Drug
D00296
KEGG Compound
C06953
PubChem Compound
50599
PubChem Substance
46506255
ChemSpider
45864
BindingDB
50404252
ChEBI
490877
ChEMBL
CHEMBL1460
Therapeutic Targets Database
DNC000528
PharmGKB
PA449301
HET
2DI
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Didanosine
ATC Codes
J05AF02 — Didanosine
AHFS Codes
  • 08:18.08.20 — Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
PDB Entries
1v3q
FDA label
Download (86.1 KB)
MSDS
Download (36.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections22
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Infections, Cytomegalovirus1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Pregnancy1
1, 2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAIDS-Related Dementia Complex / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentAntiretroviral Naive / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentEncephalopathies / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections34
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Progressive Multifocal Leukoencephalopathy1
2SuspendedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusTreatmentMalignant Lymphomas1
2WithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections2
3CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections14
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections3
3Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
4CompletedDiagnosticCardiovascular Disease (CVD) / HIV-Associated Lipodystrophy Syndrome1
4CompletedTreatmentHemophilia A / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections20
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Progressive Multifocal Leukoencephalopathy1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
Not AvailableRecruitingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnTreatmentHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1

Pharmacoeconomics

Manufacturers
  • Aurobindo pharma ltd
  • Barr laboratories inc
  • Matrix laboratories ltd
  • Bristol myers squibb co
  • Bristol myers squibb co pharmaceutical research institute
Packagers
  • Advanced Pharmaceutical Services Inc.
  • Amerisource Health Services Corp.
  • AQ Pharmaceuticals Inc.
  • A-S Medication Solutions LLC
  • Aurobindo Pharma Ltd.
  • Barr Pharmaceuticals
  • Bristol-Myers Squibb Co.
  • Dept Health Central Pharmacy
  • Kaiser Foundation Hospital
  • Murfreesboro Pharmaceutical Nursing Supply
  • Mylan
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Remedy Repack
Dosage forms
FormRouteStrength
Capsule, delayed releaseOral125 mg/1
Capsule, delayed releaseOral200 mg/1
Capsule, delayed release pelletsOral200 mg/1
Capsule, delayed release pelletsOral250 mg/1
Capsule, delayed release pelletsOral400 mg/1
Powder, for solutionOral10 mg/1mL
Tablet, for suspensionOral100 mg/1
Tablet, for suspensionOral150 mg/1
Tablet, for suspensionOral200 mg/1
TabletOral100 mg
TabletOral150 mg
TabletOral25 mg
TabletOral50 mg
Capsule, delayed releaseOral125 mg
Capsule, delayed releaseOral200 mg
Capsule, delayed releaseOral250 mg/1
Capsule, delayed releaseOral250 mg
Capsule, delayed releaseOral400 mg
Capsule, delayed releaseOral400 mg/1
Powder, for solutionOral4 g
Prices
Unit descriptionCostUnit
Videx 4 gm Solution 200ml Bottle124.51USD bottle
Videx 2 gm Solution 100ml Bottle58.4USD bottle
Videx EC 400 mg Delayed Release Capsule14.75USD capsule
Videx ec 400 mg capsule14.18USD capsule
Didanosine 400 mg Delayed Release Capsule12.78USD capsule
Videx EC 250 mg Delayed Release Capsule9.44USD capsule
Videx ec 250 mg capsule9.08USD capsule
Didanosine 250 mg Delayed Release Capsule8.18USD capsule
Videx ec 200 mg capsule7.12USD capsule
Didanosine 200 mg Delayed Release Capsule6.42USD capsule
Videx ec 125 mg capsule4.45USD capsule
Videx 4 gm pediatric solution0.6USD ml
Videx 2 gm pediatric solution0.55USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5880106No1995-01-222012-01-22Us
CA2332922No2008-02-122018-08-04Canada
CA2072573No1996-05-282011-01-03Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)160-163 °CPhysProp
water solubility15.8 mg/mLNot Available
logP-1.24SANGSTER (1993)
Predicted Properties
PropertyValueSource
Water Solubility6.58 mg/mLALOGPS
logP-0.99ALOGPS
logP-0.35ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)6.94ChemAxon
pKa (Strongest Basic)2.75ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area88.74 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity58.59 m3·mol-1ChemAxon
Polarizability22.9 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier+0.823
Caco-2 permeable-0.9019
P-glycoprotein substrateNon-substrate0.5948
P-glycoprotein inhibitor INon-inhibitor0.945
P-glycoprotein inhibitor IINon-inhibitor0.6378
Renal organic cation transporterNon-inhibitor0.8049
CYP450 2C9 substrateNon-substrate0.8065
CYP450 2D6 substrateNon-substrate0.7777
CYP450 3A4 substrateNon-substrate0.5234
CYP450 1A2 substrateNon-inhibitor0.6934
CYP450 2C9 inhibitorNon-inhibitor0.9064
CYP450 2D6 inhibitorNon-inhibitor0.9145
CYP450 2C19 inhibitorNon-inhibitor0.8646
CYP450 3A4 inhibitorNon-inhibitor0.9608
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7288
Ames testAMES toxic0.8682
CarcinogenicityNon-carcinogens0.9094
BiodegradationNot ready biodegradable0.8478
Rat acute toxicity2.0874 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9451
hERG inhibition (predictor II)Non-inhibitor0.8735
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0090000000-fed0a8ffc5839fe73fe1
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0490000000-0ac04c4f4e817e6da391
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0920000000-14a23956c10d3f6e7e9a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-0900000000-de4599cfceaa46089291
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-1900000000-10d07c81e3fc72fcfef2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-000i-1900000000-84e8bb1bea77e6b5bfca
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-6a0516d1b3cec255e050
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-fd0dfb766f1c628d170d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-3d9e0ecfaf77d867a9d9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-e0e7d0c808e14d842dbb
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-1900000000-9d4b77c3e99e9f9a2c2a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-1900000000-2bb63f71ec2e92ce075d

Taxonomy

Description
This compound belongs to the class of organic compounds known as purine 2',3'-dideoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at positions 2 and 3.
Kingdom
Organic compounds
Super Class
Nucleosides, nucleotides, and analogues
Class
Purine nucleosides
Sub Class
Purine 2',3'-dideoxyribonucleosides
Direct Parent
Purine 2',3'-dideoxyribonucleosides
Alternative Parents
Hypoxanthines / 6-oxopurines / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Tetrahydrofurans / Heteroaromatic compounds / Oxacyclic compounds / Azacyclic compounds / Primary alcohols
show 4 more
Substituents
Purine 2',3'-dideoxyribonucleoside / 6-oxopurine / Hypoxanthine / Purinone / Imidazopyrimidine / Purine / Pyrimidone / N-substituted imidazole / Pyrimidine / Heteroaromatic compound
show 17 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
purine 2',3'-dideoxyribonucleoside (CHEBI:490877)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna-dna hybrid ribonuclease activity
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q72547
Uniprot Name
Reverse transcriptase/RNaseH
Molecular Weight
65223.615 Da
References
  1. Faulds D, Brogden RN: Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection. Drugs. 1992 Jul;44(1):94-116. [PubMed:1379914]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Purine-nucleoside phosphorylase activity
Specific Function
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine ...
Gene Name
PNP
Uniprot ID
P00491
Uniprot Name
Purine nucleoside phosphorylase
Molecular Weight
32117.69 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Bocedi A, Notaril S, Narciso P, Bolli A, Fasano M, Ascenzi P: Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. [PubMed:15814459]
  2. Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P: Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005 Dec;272(24):6287-96. [PubMed:16336266]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Involved in the renal elimination of endogenous and exogenous organic anions. Functions as organic anion exchanger when the uptake of one molecule of organic anion is coupled with an efflux of one ...
Gene Name
SLC22A6
Uniprot ID
Q4U2R8
Uniprot Name
Solute carrier family 22 member 6
Molecular Weight
61815.78 Da
References
  1. Wada S, Tsuda M, Sekine T, Cha SH, Kimura M, Kanai Y, Endou H: Rat multispecific organic anion transporter 1 (rOAT1) transports zidovudine, acyclovir, and other antiviral nucleoside analogs. J Pharmacol Exp Ther. 2000 Sep;294(3):844-9. [PubMed:10945832]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nucleoside transmembrane transporter activity
Specific Function
Mediates both influx and efflux of nucleosides across the membrane (equilibrative transporter). It is sensitive (ES) to low concentrations of the inhibitor nitrobenzylmercaptopurine riboside (NBMPR...
Gene Name
SLC29A1
Uniprot ID
Q99808
Uniprot Name
Equilibrative nucleoside transporter 1
Molecular Weight
50218.805 Da
References
  1. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD: Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol. 2001 Apr-Jun;18(2):161-7. [PubMed:11463208]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Nucleoside transmembrane transporter activity
Specific Function
Mediates equilibrative transport of purine, pyrimidine nucleosides and the purine base hypoxanthine. Very less sensitive than SLC29A1 to inhibition by nitrobenzylthioinosine (NBMPR), dipyridamole, ...
Gene Name
SLC29A2
Uniprot ID
Q14542
Uniprot Name
Equilibrative nucleoside transporter 2
Molecular Weight
50112.335 Da
References
  1. Yao SY, Ng AM, Sundaram M, Cass CE, Baldwin SA, Young JD: Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol. 2001 Apr-Jun;18(2):161-7. [PubMed:11463208]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2018 20:27